Literature DB >> 34882302

Mechanism of Adipose-Derived Mesenchymal Stem Cell-Derived Extracellular Vesicles Carrying miR-21-5p in Hyperoxia-Induced Lung Injury.

Yunfei Wu1, Zhihui Zhang2, Jun Li3, Hai Zhong4, Rui Yuan5, Zihui Deng6, Xu Wu2.   

Abstract

Hyperoxia-induced lung injury (HILI) tends to develop bronchopulmonary dysplasia. Adipose-derived mesenchymal stem cell (ADMSC)-derived extracellular vesicles (EVs) hold great promise in alleviating lung injury. This study explored the mechanism of ADMSC-EVs in HILI. ADMSC-EVs were isolated and identified. The murine and cell models of HILI were established. HILI mice and cells were pre-treated with ADMSC-EVs. The lung dry/wet ratio, pathological structure, apoptosis, and inflammation of HILI mice were measured. The viability, apoptosis, and oxidative stress of HILI cells were measured. The internalization of EVs in lung and cells was observed by fluorescence labeling. The binding relationships between miR-21-5p and SKP2, and Nr2f2 and C/EBPα were analyzed. The binding of SKP2 and Nr2f2 and the Nr2f2 ubiquitination level were detected. ADMSC-EVs exerted preventive effects on HILI mice, evidenced by reduced lung dry/wet ratio, inflammation, and apoptosis in HILI mice. In vitro, EVs enhanced HILI cell viability and reduced apoptosis, inflammation, and oxidative stress. EVs carried miR-21-5p into lung cells to upregulate miR-21-5p expression and thereby target SKP2. SKP2 bound to Nr2f2 and promoted its ubiquitination degradation. EVs inhibited the binding of Nr2f2 and C/EBPα and further suppressed C/EBPα transcription. Collectively, ADMSC-EVs carrying miR-21-5p alleviated HILI via the SKP2/Nr2f2/C/EBPα axis. Role and mechanism of adipose-derived mesenchymal stem cell-derived extracellular vesicles in hyperoxia-induced lung injury. ADMSC-EVs upregulated miR-21-5p expression in cells by carrying miR-21-5p into lung cells, thereby promoting the binding of miR-21-5p and SKP2 mRNA, inhibiting the expression of SKP2, reducing the ubiquitination level of Nr2f2, increasing the expression of Nr2f2, promoting the binding of Nr2f2 and the C/EBPα promoter, upregulating C/EBPα mRNA level, and eventually alleviating HILI.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Adipose-derived mesenchymal stem cells; C/EBPα; Extracellular vesicles; Hyperoxia-induced lung injury; Nr2f2; SKP2; Ubiquitin ligase; miR-21-5p

Mesh:

Substances:

Year:  2021        PMID: 34882302     DOI: 10.1007/s12015-021-10311-x

Source DB:  PubMed          Journal:  Stem Cell Rev Rep        ISSN: 2629-3277            Impact factor:   5.739


  41 in total

Review 1.  Oxidative stress and bronchopulmonary dysplasia.

Authors:  Junyi Wang; Wenbin Dong
Journal:  Gene       Date:  2018-08-09       Impact factor: 3.688

2.  Human induced pluripotent stem cells ameliorate hyperoxia-induced lung injury in a mouse model.

Authors:  Adam Mitchell; Heather Wanczyk; Todd Jensen; Christine Finck
Journal:  Am J Transl Res       Date:  2020-01-15       Impact factor: 4.060

3.  Probucol attenuates hyperoxia-induced lung injury in mice.

Authors:  Tomonobu Kawaguchi; Toyoshi Yanagihara; Tetsuya Yokoyama; Saiko Suetsugu-Ogata; Naoki Hamada; Chika Harada-Ikeda; Kunihiro Suzuki; Takashige Maeyama; Kazuyoshi Kuwano; Yoichi Nakanishi
Journal:  PLoS One       Date:  2017-04-06       Impact factor: 3.240

Review 4.  MicroRNAs in the regulation of cellular redox status and its implications in myocardial ischemia-reperfusion injury.

Authors:  Teresa Carbonell; Aldrin V Gomes
Journal:  Redox Biol       Date:  2020-06-19       Impact factor: 11.799

5.  Fucoidan attenuates hyperoxia-induced lung injury in newborn rats by mediating lung fibroblasts differentiate into myofibroblasts.

Authors:  Yan Zhang; Hengjian Du; Xuelian Yu; Jiang Zhu
Journal:  Ann Transl Med       Date:  2020-11

6.  K2P2.1 (TREK-1) potassium channel activation protects against hyperoxia-induced lung injury.

Authors:  Tatiana Zyrianova; Benjamin Lopez; Riccardo Olcese; John Belperio; Christopher M Waters; Leanne Wong; Victoria Nguyen; Sriharsha Talapaneni; Andreas Schwingshackl
Journal:  Sci Rep       Date:  2020-12-15       Impact factor: 4.379

7.  Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study.

Authors:  Guoping Zheng; Lanfang Huang; Haijiang Tong; Qiang Shu; Yaoqin Hu; Menghua Ge; Keqin Deng; Liuya Zhang; Bin Zou; Baoli Cheng; Jianguo Xu
Journal:  Respir Res       Date:  2014-04-04

8.  Extracellular Vesicles Derived from Adipose Mesenchymal Stem Cells Alleviate PM2.5-Induced Lung Injury and Pulmonary Fibrosis.

Authors:  Yongheng Gao; Jinbo Sun; Chuan Dong; Mingxuan Zhao; Ying Hu; Faguang Jin
Journal:  Med Sci Monit       Date:  2020-04-18

9.  Caffeine prevents hyperoxia-induced lung injury in neonatal mice through NLRP3 inflammasome and NF-κB pathway.

Authors:  Shangqin Chen; Qiuping Wu; Dingjuan Zhong; Changchong Li; Lizhong Du
Journal:  Respir Res       Date:  2020-06-08

10.  Treatment of Hyperoxia-Induced Lung Injury with Lung Mesenchymal Stem Cells in Mice.

Authors:  Yabo Mei; Chong Chen; Hui Dong; Wanqiao Zhang; Yan Wang; Ming Chi; Zhichun Feng
Journal:  Stem Cells Int       Date:  2018-09-26       Impact factor: 5.443

View more
  3 in total

Review 1.  Stem-Cell Therapy for Bronchopulmonary Dysplasia (BPD) in Newborns.

Authors:  Said A Omar; Amal Abdul-Hafez; Sherif Ibrahim; Natasha Pillai; Mohammed Abdulmageed; Ranga Prasanth Thiruvenkataramani; Tarek Mohamed; Burra V Madhukar; Bruce D Uhal
Journal:  Cells       Date:  2022-04-09       Impact factor: 7.666

Review 2.  Mesenchymal Stromal Cell-Derived Extracellular Vesicles for Neonatal Lung Disease: Tiny Particles, Major Promise, Rigorous Requirements for Clinical Translation.

Authors:  Flore Lesage; Bernard Thébaud
Journal:  Cells       Date:  2022-03-31       Impact factor: 6.600

Review 3.  Roles of exosomes and exosome-derived miRNAs in pulmonary fibrosis.

Authors:  Yongfeng Yang; Hong Huang; Yi Li
Journal:  Front Pharmacol       Date:  2022-08-11       Impact factor: 5.988

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.